Astel­las, Pfiz­er scrap a PhI­II breast can­cer study us­ing Xtan­di; New $30M fund will back Is­raeli biotech star­tups

→ NanoS­tring Tech­nolo­gies notes in an SEC fil­ing that Astel­las and Pfiz­er have de­cid­ed to ter­mi­nate the late-stage EN­DEAR tri­al, which the com­pa­ny was in­volved with. The two com­pa­nies re­vealed that de­ci­sion in a foot­note to a re­cent re­lease. “Ad­di­tion­al­ly, Pfiz­er and Astel­las an­nounced the dis­con­tin­u­a­tion of the planned EN­DEAR tri­al (A Phase III, Ran­dom­ized, In­ter­na­tion­al Study Com­par­ing the Ef­fi­ca­cy and Safe­ty of En­za­lu­tamide (Xtan­di) in Com­bi­na­tion With Pa­cli­tax­el Chemother­a­py or as Monother­a­py Ver­sus Place­bo With Pa­cli­tax­el in Pa­tients With Ad­vanced, Di­ag­nos­tic-Pos­i­tive, Triple-Neg­a­tive Breast Can­cer); no pa­tients were ever en­rolled in the tri­al. Fur­ther­more, the com­pa­nies have de­cid­ed that based on the da­ta from the en­za­lu­tamide Phase 2 HER2+ and ER/PR+ breast can­cer stud­ies, there will not be fol­low-on Phase 3 stud­ies at this time.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER